Skip to main content
PMC home page
American Journal of Alzheimer's Disease and Other Dementias logoLink to American Journal of Alzheimer's Disease and Other Dementias
. 2008 Apr-May;23(2):150–161. doi: 10.1177/1533317507312957

Alzheimer's and Non-Alzheimer's Dementia: A Critical Review of Pharmacological and Nonpharmacological Strategies

Sahoo Saddichha 1, Vibha Pandey 2
PMCID: PMC10846026  PMID: 18332476

Abstract

Objective. Dementia is an age-related progressive neurodegenerative disorder afflicting about 5% of the world's population, and it is expected to grow dramatically in the future keeping in view our ageing society. Currently available medications appear to be able to produce moderate symptomatic benefits but do not to stop disease progression. In this article, the management of the disorder, including the currently available drugs as well as psychosocial strategies, is discussed. Methods. A computerized search on Pubmed from 1980 to 2006 was carried out and all articles evaluated and graded on NICE guidelines. Results and conclusions. Currently evaluated and accepted medications only bring about a reduction in the deteriorating course. A combination of pharmacotherapy and psychosocial management is the need of the hour.

Keywords: dementia, Alzheimer's dementia, non-Alzheimer's dementia, psychosocial management, current trends in management

Full Text

The Full Text of this article is available as a PDF (96.0 KB).

Contributor Information

Sahoo Saddichha, Central Institute of Psychiatry, Ranchi, Jharkhand, India, saddichha@gmail.com .

Vibha Pandey, Central Institute of Psychiatry, Ranchi, Jharkhand, India.

References

  1. Neugroschl JA , Kolevzon A., Samuels SC, Marin DB Dementia. In: Sadock BJ, Sadock VA, eds. Comprehensive Textbook of Psychiatry. Philadelphia, PA: Lippincott Williams & Wilkins; 2005:1068-1093. [Google Scholar]
  2. Alzheimer's Society. Demography-Policy position paper. http://www.alzheimers.org.uk/site/scripts/documents_info.php?documentID=412&pageNumber=1. Published 2003. Accessed June 27, 2007. [Google Scholar]
  3. Eisai Alzheimer's Worldwide. Alzheimer's disease worldwide. http://www.eisai.co.uk/worldwide.htm . Published 2003. Accessed June 25, 2007. [Google Scholar]
  4. Brodaty H., Gresham M., Luscombe G. The Prince Henry Hospital dementia caregivers' training programme . Int J Geriatr Psychiatry. 1997;12:183-192. [DOI] [PubMed] [Google Scholar]
  5. World Health Organization. International Classification of Diseases (ICD 10). Geneva: , Switzerland: World Health Organization; 1992. [Google Scholar]
  6. American Psychiatric Association. Diagnosis and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994. [Google Scholar]
  7. Flicker L., LoGiudice D., Carlin JB, Ames D. The predictive value of dementia screening instruments in clinical populations . Int J Geriatr Psychiatry. 1997;12:203-209. [DOI] [PubMed] [Google Scholar]
  8. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56:1143-1153. [DOI] [PubMed] [Google Scholar]
  9. Eastley R., Wilcock G. Assessment and differential diagnosis of dementia. In: O'Brien J, Ames D , Burns A, eds. Dementia. 2nd ed. London: Arnold; ; 2000. [Google Scholar]
  10. AGS Clinical Practice Committee. Guidelines abstracted from the American Academy of Neurology's dementia guidelines for early detection, diagnosis, and management of dementia. J Am Geriatr Soc. 2003;51:869-873. [DOI] [PubMed] [Google Scholar]
  11. Celsis P. Age related cognitive decline, mild cognitive impairment or pre clinical Alzheimer's disease. Ann Med. 2000;32:6-14. [DOI] [PubMed] [Google Scholar]
  12. LoGiudice D. Dementia: an update to refresh your memory . Inter Med J. 2002;32:535-540. [DOI] [PubMed] [Google Scholar]
  13. Doody RS, Stevens JC, Beck C., et al. Practice parameter: management of dementia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56: 1154-1166. [DOI] [PubMed] [Google Scholar]
  14. Brodaty H., Ames D., Boundy KL, et al. Pharmacological treatment of cognitive deficits in Alzheimer's disease. Med J Aust. 2001;175:324-329. [DOI] [PubMed] [Google Scholar]
  15. Passmore AP , Bayer AJ, Steinhagen-Thiessen E. Cognitive, global, and functional benefits of donepezil in Alzheimer's disease and vascular dementia: results from large-scale clinical trials. J Neurol Sci. 2005; 229:141-146. [DOI] [PubMed] [Google Scholar]
  16. Moretti R., Torre P., Antonello RM, Cazzato G., Bava A. Rivastigmine in subcortical vascular dementia: an open 22-month study. J Neurol Sci. 2002;203:141-146. [DOI] [PubMed] [Google Scholar]
  17. Erkinjuntti T., Kurz A., Gauthier S., Bullock R., Lilienfeld S., Damaraju CV Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet. 2002;359:1283-1290. [DOI] [PubMed] [Google Scholar]
  18. Wilcock G., Möbius HJ, Stöffler A. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol . 2002;17:297-305. [DOI] [PubMed] [Google Scholar]
  19. Jick H., Zornberg GL, Jick SS, Seshadri S., Drachman DA Statins and the risk of dementia. Lancet. 2000;356: 1627-1631. [DOI] [PubMed] [Google Scholar]
  20. Pantoni L., del Ser T., Soglian AG, et al. Efficacy and safety of nimodipine in subcortical vascular dementia: a randomized placebo-controlled trial. Stroke. 2005;36: 619-624. [DOI] [PubMed] [Google Scholar]
  21. Bar KJ, Franke S., Wenda B., et al. Pentosidine and N(epsilon)-(carboxymethyl)-lysine in Alzheimer's disease and vascular dementia. Neurobiol Aging. 2003;24:333-338. [DOI] [PubMed] [Google Scholar]
  22. Rother M., Erkinjuntti T., Roessner M., Kittner B., Marcusson J., Karlsson I. Propentofylline in the treatment of Alzheimer's disease and vascular dementia . Dement Geriatr Cogn Disord. 1998. ;9:36-43. [DOI] [PubMed] [Google Scholar]
  23. McKeith IG, Del-Ser T., Anand R., et al. Rivastigmine provides symptomatic benefit in dementia with Lewy bodies: findings from placebo-controlled international multicenter study. Neurology. 2000;54:A450. [Google Scholar]
  24. Barber R., Pannikar A., McKeith IG Dementia with Lewy bodies: diagnosis and management. Int J Geriatr Psychiatry. 2001;16:S12-S18. [DOI] [PubMed] [Google Scholar]
  25. Moretti R., Torre P., Antonello RM, Cazzato G., Bava A. Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study. Eur Neurol . 2003;49:13-19. [DOI] [PubMed] [Google Scholar]
  26. Moretti R., Torre P., Antonello RM, Cazzato G., Bava A. Effects of selegiline on fronto-temporal dementia: a neuropsychological evaluation . Int J Geriatr Psychiatry. 2002;17:391-392. [DOI] [PubMed] [Google Scholar]
  27. Jones G., Power C. Regulation of neural cell survival by HIV-1 infection. Neurobiol Dis. 2006;21:1-17. [DOI] [PubMed] [Google Scholar]
  28. Brown P. Drug therapy in human and experimental transmissible spongiform encephalopathy . Neurology. 2002;58:1720-1725. [DOI] [PubMed] [Google Scholar]
  29. Ross CA, Margolis RL Huntington's disease. Clin Neurosci Res. 2001. ;1:142-152. [Google Scholar]
  30. Jann MW, Pharm D., Small GW Cholinesterase inhibitors and similarly acting compounds. In: Sadock BJ, Sadock VA, eds. Comprehensive Textbook of Psychiatry. Philadelphia, PA: Lippincott Williams & Wilkins; 2005: 2808-2817. [Google Scholar]
  31. Wilcock GK, Whitehead A., Evans JG, Birks J., Perdomo C., Pratt RD Donepezil: a meta-analysis of individual patient's data from randomized controlled trials in the treatment of patients with mild to moderate Alzheimer's disease . Neurology. 2001;56(suppl 3):339. [DOI] [PubMed] [Google Scholar]
  32. Rosler M., Anand R., Cicin-Sain A., et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomized controlled trial. Br Med J. 1999;318:663-668. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Tariot PN, Solomon PR, Morris JC, Kershaw P., Lilienfeld S., Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology. 2000;54:2269-2276. [DOI] [PubMed] [Google Scholar]
  34. Shua-Haim JR , Ross JS Current and the near future medications for Alzheimer's Disease. What can we expect from them? Am J Alzheimers Dis Other Demen. 1999;14(suppl):294-307. [Google Scholar]
  35. de Jongh P. Clinical Development of Metrifonate: An Overview of Cognitive and Global Outcomes. Collegium Internationale Neuro-Psychopharmacologium. Glasgow, Scotland: Bayer AG; 1998. [Google Scholar]
  36. Dubois B., McKeith I., Orgogozo J., Collins O., Meulien D. Multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild to moderate Alzheimer's disease. Int J Geriatr Psychiatry . 1999;14:973-982. [PubMed] [Google Scholar]
  37. Shikiar R., Shakespeare A., Sagnier P., et al. The impact of metrifonate therapy on caregivers of patients with Alzheimer's disease: results from MALT clinical trial. J Am Geriatr Soc. 2000;48:268-274. [DOI] [PubMed] [Google Scholar]
  38. Becker R., Giacobini E., Elble R., McIlhany M., Sherman K. Potential pharmacotherapy of Alzheimer's disease. A comparison of various forms of physostigmine administration. Acta Neurol Scand Suppl . 1988;77:19-32. [DOI] [PubMed] [Google Scholar]
  39. Reisberg B., Doody R., Stöffler A., Schmitt F., Ferris S., Möbius HJ; Memantine Study Group. Memantine in moderate to severe Alzheimer's disease. N Engl J Med. 2003;348:1333-1341. [DOI] [PubMed] [Google Scholar]
  40. Pomara N., Peskind ER, Potkin SG, et al. Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: a randomised controlled trial. Neurobiol Aging. 2004;25(suppl 2):19.14675725 [Google Scholar]
  41. Rive B., Vercelletto M., Damier FD, Cochran J., Francois C. Memantine enhances autonomy in moderate to severe Alzheimer's disease . Int J Geriatr Psychiatry. 2004;19: 458-464. [DOI] [PubMed] [Google Scholar]
  42. López-Arrieta, Birks J. Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst Rev. 2007;(1):CD000147. doi:10.1002/14651858. CD000147. [DOI] [PubMed] [Google Scholar]
  43. Frampton M. , Harvey RJ, Kirchner V. Propentofylline for dementia. Cochrane Database Syst Rev. 2003. ;(2): CD002853.doi:10.1002/14651858.CD002853. [DOI] [PubMed] [Google Scholar]
  44. McGuire D., Marder K. Pharmacological frontiers in the treatment of AIDS dementia. J Psychopharmacol. 2000; 14:251-257. [DOI] [PubMed] [Google Scholar]
  45. Wilkinson D. Drugs for treatment of Alzheimer's disease . Int J Clin Pract. 2001;55:129-34. [PubMed] [Google Scholar]
  46. Kumar R., Orgogozo J. Efficacy and safety of SB202026 as a symptomatic treatment for Alzheimer's disease. Neurobiol Aging. 1996;17:161. [Google Scholar]
  47. Olanow CW A radical hypothesis for neurodegeneration. Trends Neurosci . 1993;16:439-444. [DOI] [PubMed] [Google Scholar]
  48. Sano M., Ernesto C., Thomas RG, et al. A controlled trial of selegiline, α-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Eng J Med. 1997;336:1216-1222. [DOI] [PubMed] [Google Scholar]
  49. Aisen PS, Davis KL The search for disease-modifying treatment for Alzheimer's disease . Neurology. 1997;48 (suppl):35S-41S. [DOI] [PubMed] [Google Scholar]
  50. Morris MC, Evans DA, Bienias JL, et al. Dietary intake of antioxidant nutrients and the risk of incident of Alzheimer's disease in a biracial community study. JAMA . 2002;287:3230-3237. [DOI] [PubMed] [Google Scholar]
  51. Jansen SL, Forbes DA, Duncan V., Morgan DG Melatonin for cognitive impairment. Cochrane Database Syst Rev. 2006;(1):CD003802.doi:10.1002/14651858.CD003802. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Fioravanti M., Flicker L. Nicergoline for dementia and other age associated forms of cognitive impairment. Cochrane Database Syst Rev. 2001;(4):CD003159.doi: 10.1002/14651858.CD003159. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Rogers J., Kirby LC, Hempelman SR, et al. Clinical trial on indomethacin in Alzheimer's disease. Neurology. 1993;43:1609-1611. [DOI] [PubMed] [Google Scholar]
  54. Scharf S., Mander A., Ugoni A., Vajda F., Christophidis N. A double-blind, placebo controlled trial of diclofenac/ misoprostol in Alzheimer's disease. Neurology. 1999; 53:197-201. [DOI] [PubMed] [Google Scholar]
  55. Aisen PS, Davis KL, Berg JD, et al. A randomized controlled trial of prednisone in Alzheimer's disease . The Alzheimer's Disease Cooperative study. Neurology. 2000; 54:588-593. [DOI] [PubMed] [Google Scholar]
  56. Schneider LS , Farlow MR, Pogoda JM Potential role of estrogen replacement in the treatment of Alzheimer's dementia. Am J Med. 1997;103(suppl 3A):46S-50S. [DOI] [PubMed] [Google Scholar]
  57. Nathan L., Chaudhuri G. Antioxidant and pro-oxidant actions of estrogens: potential physiological and clinical implications. Semin Reprod Endocrinol. 1998;16:309-314. [DOI] [PubMed] [Google Scholar]
  58. Inestrosa NC , Marzolo MP, Bonnefont AB Cellular and molecular basis of estrogen's neuroprotection. Potential relevance for Alzheimer's disease . Mol Neurobiol 1998; 17:73-86. [DOI] [PubMed] [Google Scholar]
  59. Rockwood K. , Kirkland S., Hogan DB, et al. Use of lipid lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol. 2002;59:223-227. [DOI] [PubMed] [Google Scholar]
  60. Hijjar I., Schumert J., Hirth V., Wieland D., Eleazer GP The impact of statins on the prevalence of dementia and the progression of cognitive impairment. J Gerontol A Biol Sci. 2002;M414-M418. [DOI] [PubMed] [Google Scholar]
  61. Fassbender K., Simons M., Bergmann C., et al. Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo. Proc Natl Acad Sci U S A. 2001. ;98:5856-5861. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Locatelli S. , Lutjohann D., Schmidt HH, Otto C., Beisiegel U., von Bergmann K. Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high dosage simvastatin in patients with hypercholesterolemia: evidence that simvastatin affects cholesterol metabolism in the human brain . Arch Neurol . 2002;59:213-216. [DOI] [PubMed] [Google Scholar]
  63. Scott HD, Laake K. Statins for the reduction of risk of Alzheimer's disease. Cochrane Database Syst Rev. 2001:(4): CD003160. [DOI] [PubMed] [Google Scholar]
  64. Flaherty DB , Soria JP, Tomasiewicz HG, Wood JG Phosphorylation of human tau protein by microtubuleassociate kinase: GSK3beta and cdk5are key participants. J Neurosci Res. 2000;62:463-472. [DOI] [PubMed] [Google Scholar]
  65. Sang H., Lu Z., Li Y., Ru B., Wang, Chen J. Phosphorylation of tau by glycogen synthase kinase 3beta in intact mammalian cells influences the stability of microtubules. Neurosci Lett. 2001;312:141-144. [DOI] [PubMed] [Google Scholar]
  66. Chen G., Huang LD, Jiang YM, Manji HK The mood stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J Neurochem. 1999;72: 1327-1330. [DOI] [PubMed] [Google Scholar]
  67. Martinez A. , Alonso M., Castro A., Perez C., Moreno FJ First non-ATP competitive glycogen synthase 5 beta (GSK-3 beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheirmer's disease. J Med Chem. 2002;45:1292-1299. [DOI] [PubMed] [Google Scholar]
  68. Englels HJ, Wirth JC No ergogenic effects of ginseng during graded maximal aerobic exercise . J Am Diet Assoc. 1997;97:1110-1115. [DOI] [PubMed] [Google Scholar]
  69. Bai DL, Tang XC, He XC Huperzine A, a potential therapeutic agent for treatment of Alzheimer's disease . Curr Med Chem. 2000;7:355-374. [DOI] [PubMed] [Google Scholar]
  70. Ou LY, Tang XC, Cai JX Effect of huperzine A on working memory in reserpine- or yohimbine-treated monkeys. Eur J Pharmacol. 2001;433:151-156. [DOI] [PubMed] [Google Scholar]
  71. Pepping J. Huperzine A. Am J Health Syst Pharm. 2000; 57:533-534. [DOI] [PubMed] [Google Scholar]
  72. Gelinas DS, DaSilva K., Fenili D., George PS, McLaurin J. Immunotherapy for Alzheimer's disease. Proc Natl Acad Sci U S A. 2004;101(suppl 2):14657-14662. [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Paganetti P. , Calanca V., Galli C., Stefani M., Molinari M. β-site specific intrabodies to decrease and prevent generation of Alzheimer's Aβ peptide. J Cell Biol. 2005;168: 863-868. [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Arbel M., Yacoby I., Solomon B. Inhibitor of amyloid precursor protein processing by β-secretase through site directed antibodies. Proc Natl Acad Sci U S A . 2005;102: 7718-7723. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Li Y., Wang H., Wang S., Quon D., Liu YW, Cordell B. Positive and negative regulation of APP amyloidogenesis by sumoylation . Proc Natl Acad Sci U S A. 2003;100:259-264. [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. Verger A., Perdomo J., Crossley M. Modification with SUMO. A role in transcriptional regulation. EMBO Rep. 2003;4:137-142. [DOI] [PMC free article] [PubMed] [Google Scholar]
  77. Lee JY, Friedman JE, Angel L., Kozak A., Koh JY The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human b-amyloid precursor protein transgenic mice. Neurobiol Aging. 2004;25:1315-1321. [DOI] [PubMed] [Google Scholar]
  78. Hsiao K., Chapman P., Nilsen S., et al. Correlative memory deficits, Aβ elevation and amyloid plaques in transgenic mice. Science. 1996;274:99-102. [DOI] [PubMed] [Google Scholar]
  79. Foxall G., Leek S., Maddock S. Cognitive antecedents of consumers' willingness to purchase fish rich in polyunsaturated fatty acids (PUFA). Appetite. 1998;31:391-402. [DOI] [PubMed] [Google Scholar]
  80. Bates J., Boote J., Beverley C. Psychosocial interventions for people with a milder dementing illness: a systematic review. J Adv Nurs. 2004;45:644-656. [DOI] [PubMed] [Google Scholar]
  81. Emerson E. Working with people with challenging behaviour. In: Emerson E, Hatton J, Bromley J, Caine A, eds. Clinical Psychology and People with Intellectual Disabilities . Chichester, UK: John Wiley; 1998:127-153. [Google Scholar]
  82. Burgio L., Fisher S. Application of psychosocial interventions for treating behavioural and psychological symptoms of dementia. Int Psychogeriatr . 2000. ;12(suppl 1):351-358. [Google Scholar]
  83. Woods RT Psychological Problems of Ageing. Chichester, UK: John Wiley; 1999. [Google Scholar]
  84. Bourgeois MS Conversing with Memory Impaired Individuals' Aids: A Memory Aid Workbook. Bicester, UK: Winslow Press; 1992. . [Google Scholar]
  85. Teri L., Gallagher-Thompson D. Cognitive-behavioural interventions for treatment of depression in Alzheimer's patients. Gerontologist. 1991;31:413-416. [DOI] [PubMed] [Google Scholar]
  86. Kipling T., Bailey M., Charlesworth G. The feasibility of a cognitive behavioural therapy group for men with a mild/ moderate cognitive impairment. Behav Cogn Psychother . 1999;27:189-193. [Google Scholar]
  87. Baldelli MV , Pirani A., Motta M., Abati E., Mariani E., Manzi V. Effects of reality orientation therapy on elderly patients in the community. Arch Gerontol Geriatr. 1993; 17:211-218. [DOI] [PubMed] [Google Scholar]
  88. Zanetti O., Binetti G., Magni E., Rozzini L., Bianchetti A., Trabucchi M. Procedural memory stimulation in Alzheimer's disease: impact of a training programme. Acta Neurol Scand. 1997. ;95:152-157. [DOI] [PubMed] [Google Scholar]
  89. Spector A., Orrell M., Davies S., Woods B. Reality orientation for dementia. Cochrane Library. 2002;(3). Oxford, UK: Update Software; . [Google Scholar]
  90. Kasl-Godley J., Gatz M. Psychosocial interventions for individuals with dementia: an integration of theory, therapy, and a clinical understanding of dementia. Clin Psychol Rev. 2000;6:755-782. [DOI] [PubMed] [Google Scholar]
  91. Weiner MF Practical Psychotherapy. New York, NY: Brunner; /Mazel; 1986. [Google Scholar]
  92. Feil N. Group therapy in a home for the aged. Gerontologist . 1967;7:192-195. [DOI] [PubMed] [Google Scholar]
  93. Hitch S. Cognitive therapy as a tool for the caring elderly confused person . J Clin Nurs. 1994;3:49-55. [DOI] [PubMed] [Google Scholar]
  94. Neal M., Briggs M. Validation therapy for dementia. Cochrane Library. 2002;(3). Oxford, UK: Update Software; . [Google Scholar]
  95. Teri L., Logsdon RG, Uomoto J., McCurry SM Behavioral treatment of depression in dementia patients: a controlled clinical trial. J Gerontol B Psychol Sci Soc Sci. 1997. ;52:P159-P166. [DOI] [PubMed] [Google Scholar]
  96. Spector A., Orrell M., Davies S., Wood B. Reminiscence therapy for dementia. Cochrane Library. 2002;(3). Oxford, UK: Update Software. [Google Scholar]
  97. Gibson F. What can reminiscence contribute to people with dementia? In: Bornat J, ed. Reminiscence reviewed: Evaluations, achievements, perspectives. Buckingham, UK: Open University Press; 1994:46-60. [Google Scholar]
  98. O'Donovan S. The memory lingers on. Elderly Care. 1993;5:27-31. [PubMed] [Google Scholar]
  99. Haight BK The therapeutic role of a structured life-review process in homebound elderly subjects. J Gerontol. 1988;43:40-44. [DOI] [PubMed] [Google Scholar]
  100. Buechel H. Reminiscence: a review and prospectus. Phys Occup Ther Geriatr. 1986;5:25-37. [Google Scholar]
  101. Woods P., Ashley J. Simulated presence therapy: using selected memories to manage problem behaviors in Alzheimer's disease patients. Geriatr Nurs. 1995;16:9-14. [DOI] [PubMed] [Google Scholar]
  102. Cohen-Mansfield J., Werner P. Management of verbally disruptive behaviors in nursing home residents. J Gerontol A Biol Sci Med Sci. 1997;52:M369-M377. [DOI] [PubMed] [Google Scholar]
  103. Snyder M., Egan EC, Burns KR Efficacy of hand massage in decreasing agitation behaviors associated with care activities in persons with dementia. Geriatr Nurs . 1995;16:60-63. [DOI] [PubMed] [Google Scholar]
  104. Churchill M., Safaoui J., McCabe B., Baun MM Using a therapy dog to alleviate the agitation and desocialization of people with Alzheimer's disease. J Psychosoc Nurs Ment Health Serv. 1999;37:16-22. [DOI] [PubMed] [Google Scholar]
  105. Ford M., Fox J., Fitch S., Donovan A. Light in the darkness. Nurs Times. 1987;83:26-29. [PubMed] [Google Scholar]

Articles from American Journal of Alzheimer's Disease and Other Dementias are provided here courtesy of SAGE Publications

RESOURCES